Padcev (enfortumab vedotin)

pCPA File Number: 21705
Negotiation Status:
Under consideration for negotiation
Indication(s):
Treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy
Sponsor/Manufacturer:
Seagen Canada Inc.
CADTH Project Number:
PC0251-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable